What is CagriSema, and what does the search ask?
The two phase 3 papers describe CagriSema as the coadministration of cagrilintide and semaglutide, the combination studied for weight management [1][2]. Cagrilintide is a long-acting amylin analogue, listed as investigational in the library; semaglutide is FDA approved and has its own labels [4]. Amylin and GLP-1 act on different receptors, which is why the two were studied together, and the papers report the result of the pair rather than each part's share of it [1].
People searching the name want to know what it is, how it compared with semaglutide alone, and what amounts were studied. The first two have published answers. The third is left to the papers themselves: their study assignments describe research populations, and this page does not restate them as a schedule for anyone.
What do the CagriSema phase 3 studies report?
REDEFINE 1, published in 2025, was a 68-week, double-blind phase 3a study of 3417 adults without diabetes who had obesity, or overweight with a related condition [1]. Participants were randomly assigned to the combination, to semaglutide alone, to cagrilintide alone, or to placebo, each with lifestyle support. Mean body-weight change at 68 weeks was 20.4% lower with the combination and 3.0% lower with placebo. Gastrointestinal adverse events affected 79.6% of the combination group and 39.9% of the placebo group, mostly mild to moderate and transient.
REDEFINE 2, published alongside it, enrolled 1206 adults with type 2 diabetes and a body-mass index of 27 or more, assigned 3 to 1 to the combination or placebo for 68 weeks [2]. Mean weight change was 13.7% lower against 3.4% lower, and 73.5% of the combination group reached a glycated haemoglobin of 6.5% or less, against 15.9% on placebo.
An earlier 2021 phase 1b study measured cagrilintide pharmacokinetics alongside semaglutide and reported a cagrilintide half-life of 159 to 195 hours [3]. The figure in this section shows reported group means from the two phase 3 papers; they describe study populations and are not an expected outcome for any one person.
| Compound | Status | Half-life input | Package example |
|---|---|---|---|
| Cagrilintide | Investigational | 168 h | 5 mg (vendor listing) |
| Semaglutide | FDA-labeled presentation | 168 h | 10 mg (vendor listing) |
How is CagriSema measured and converted?
No source on this page describes a CagriSema presentation to convert, so there is no stated combined pen, no concentration and no syringe-unit figure, and this page does not build one by adding two amounts together [1]. Each component is measured on its own, from its own package.
The library's half-life input is 168 hours for each compound, which puts a single modeled contribution at half its starting value after 7 days and at a quarter after 14 [4][5]. For vial arithmetic, the cagrilintide calculator and the semaglutide calculator each divide their own labeled amount by their own volume; the two are never mixed into one figure.
How do people log cagrilintide and semaglutide in PinPoint?
Both compounds are in PinPoint's library, so each is logged as its own entry with compound, dose, site and pain level [6][4]. Each record keeps its own schedule, set by the user, with reminders tied to the day and time set [6].
The Home curve models each compound from its own 168 hour input, as a mathematical visualization of published population averages that does not account for individual variation [6][4]. Weight, side effects with severity ratings and daily notes can be recorded beside both, and prefilled pens and vials are tracked side by side [6].
Get PinPoint on the App StoreWhat do people ask about CagriSema?
- What is CagriSema?
- CagriSema is the development name for cagrilintide, an amylin analogue, given with semaglutide, a GLP-1 receptor agonist. The 2025 phase 3 papers describe it as investigational.
- How much weight did people lose on CagriSema in phase 3?
- In REDEFINE 1, mean body weight was 20.4% lower at 68 weeks against 3.0% on placebo. In REDEFINE 2, in adults with type 2 diabetes, it was 13.7% against 3.4%.
- Is CagriSema FDA approved?
- The 2025 phase 3 papers describe the combination as investigational, and this page cites no approval record for it. Semaglutide alone has FDA labels, covered in its own guide.
- Can CagriSema be tracked in one app?
- PinPoint records cagrilintide and semaglutide as two separate compounds with separate schedules and curves. PinPoint is a tracking and unit-conversion tool, and its modeled curves do not account for individual variation.
Where do these facts come from?
Sources are listed by kind: labels first, then peer-reviewed papers, then PinPoint's own library, arithmetic and app description. Library values were retrieved from the PinPoint application on 5 October 2026; vendor listings support package sizes only.
- Coadministered cagrilintide and semaglutide in adults with overweight or obesity, 2025New England Journal of Medicine, 2025 (REDEFINE 1). Phase 3a, 68 weeks, 3417 participants; combination, each component alone, or placebo.Retrieved 2026-10-05 · study
- Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes, 2025New England Journal of Medicine, 2025 (REDEFINE 2). Phase 3a, 68 weeks, 1206 participants, 3:1 to combination or placebo.Retrieved 2026-10-05 · study
- Cagrilintide with semaglutide 2.4 mg, phase 1b study, 2021The Lancet, 2021. Ascending-dose study of cagrilintide with semaglutide over 20 weeks; pharmacokinetics including cagrilintide half-life of 159 to 195 hours.Retrieved 2026-10-05 · study
- PinPoint compound library, application recordsHalf-life inputs, routes, frequencies, package examples and confidence labels as stored in the iOS app library and mirrored in the peptide guides.Retrieved 2026-10-05 · library
- Unit conversion arithmeticConcentration = amount / volume; volume = amount / concentration; U-100 units = mL x 100; remaining fraction = 2^(-elapsed / half-life).Retrieved 2026-10-05 · arithmetic
- PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description